From the Research
CD4+ breast cancer treatment should prioritize hormone receptor-positive and HER2-negative status, with a focus on endocrine therapy and targeted therapy, as there is no specific treatment for CD4+ breast cancer, which refers to immune cells rather than a breast cancer subtype. The standard approach includes surgery, radiation therapy, and systemic treatments such as chemotherapy, hormone therapy, or targeted therapy depending on the tumor's receptor status. For hormone receptor-positive breast cancers, endocrine therapy with tamoxifen or aromatase inhibitors like anastrozole, letrozole, or exemestane is recommended 1. Additionally, CDK4/6 inhibitors have shown promise in improving progression-free survival and overall survival in selected patients with HR+/HER2- metastatic breast cancer 2, 3. Treatment decisions should be individualized based on cancer stage, molecular subtype, patient age, menopausal status, and overall health status, with regular monitoring for treatment response and side effects throughout the treatment course. Some key points to consider in treatment include:
- The use of CDK4/6 inhibitors, mTOR inhibitors, and PI3K inhibitors in combination with endocrine therapy to delay initiation of chemotherapy 1, 2
- The potential benefits of adding pertuzumab to trastuzumab and an aromatase inhibitor for HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer 4
- The importance of ongoing clinical trials to further understand the role of targeted therapy in HR+/HER2- breast cancer and to identify new treatment options 5, 3